Valuation ratios measure the quantity of an asset or flaw (e.g., earnings) associated with ownership of a specified claim (e.g., a share of ownership of the enterprise).
Historical Valuation Ratios (Summary)
Based on: 10-Q (reporting date: 2026-09-30), 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
The valuation metrics exhibit a distinct cycle of rapid expansion peaking in late 2023, followed by a prolonged period of contraction and stabilization through 2025 and 2026. This pattern suggests a phase of high market optimism or speculative pricing that eventually normalized as earnings and operational results likely caught up with the stock price.
- Price to Earnings (P/E) Ratio
- A significant upward trajectory is observed from March 2022 (45.29) to a peak of 135.24 in December 2023. Following this peak, the ratio entered a consistent decline, reaching a low of 34.82 by March 2026. The period concludes with a moderate recovery to 46.86 in September 2026, returning the valuation to levels similar to the beginning of the observed period.
- Price to Operating Profit (P/OP) Ratio
- The P/OP ratio closely mirrors the P/E trend, ascending from 36.49 in March 2022 to a maximum of 109.75 in December 2023. A subsequent correction saw the ratio drop to 27.92 in March 2026, before trending upward to 37.05 by September 2026. This correlation suggests that the valuation volatility was driven by overall profit expectations rather than specific non-operating items.
- Price to Sales (P/S) Ratio
- Valuation relative to revenue grew steadily from 9.47 in early 2022, peaking at 20.77 in December 2023. Unlike the earnings-based ratios, the P/S ratio remained elevated longer, staying above 18.00 through September 2024. A sharper correction occurred in 2025, with the ratio falling to 11.39 in June 2025, before stabilizing in the 12.00 to 15.00 range through September 2026.
- Price to Book Value (P/BV) Ratio
- The P/BV ratio demonstrates substantial volatility, increasing from 29.75 in March 2022 to a peak of 65.80 in December 2023. This represents a significant premium over book value. The ratio then contracted sharply, reaching 28.21 in March 2026, indicating a realignment of the market price with the company's accounting equity.
Across all four metrics, the synchronization of the peaks in December 2023 indicates a period of maximum valuation expansion. The subsequent decline across all ratios suggests a systematic decompression of multiples, resulting in a more conservative valuation profile by the end of the reporting period in September 2026.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Price to Earnings (P/E)
| Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | 940,745,031 | 941,357,065 | 941,741,406 | 943,357,420 | 945,383,757 | 946,456,759 | 947,735,651 | 948,169,999 | 949,315,694 | 950,425,778 | 950,405,386 | 950,164,452 | 949,307,237 | 949,295,173 | 949,272,933 | 950,296,118 | 950,177,900 | 950,174,817 | 950,159,559 | ||||||
| Selected Financial Data (US$) | |||||||||||||||||||||||||
| Net income (loss) (in millions) | 6,451) | 7,095) | 7,396) | 6,638) | 5,583) | 5,661) | 2,759) | 4,410) | 970) | 2,967) | 2,243) | 2,190) | (57) | 1,763) | 1,345) | 1,938) | 1,452) | 953) | 1,903) | ||||||
| Earnings per share (EPS)2 | 29.32 | 28.38 | 26.84 | 21.88 | 19.48 | 14.58 | 11.72 | 11.17 | 8.82 | 7.73 | 6.46 | 5.52 | 5.25 | 6.84 | 5.99 | 6.57 | 6.35 | 5.99 | 6.45 | ||||||
| Share price1, 3 | 1,373.70 | 1,169.86 | 934.60 | 1,038.27 | 844.50 | 640.86 | 794.10 | 867.05 | 846.83 | 845.31 | 781.10 | 745.91 | 580.29 | 521.60 | 390.35 | 329.07 | 352.58 | 305.79 | 292.13 | ||||||
| Valuation Ratio | |||||||||||||||||||||||||
| P/E ratio4 | 46.86 | 41.23 | 34.82 | 47.45 | 43.36 | 43.95 | 67.76 | 77.63 | 96.05 | 109.42 | 120.94 | 135.24 | 110.43 | 76.21 | 65.16 | 50.08 | 55.53 | 51.05 | 45.29 | ||||||
| Benchmarks | |||||||||||||||||||||||||
| P/E Ratio, Competitors5 | |||||||||||||||||||||||||
| AbbVie Inc. | 48.88 | 68.64 | 97.96 | 94.06 | 159.78 | 92.57 | 77.73 | 79.59 | 69.16 | 62.04 | 48.26 | 63.84 | 38.27 | 30.55 | 34.43 | 22.62 | 19.16 | 19.44 | 21.64 | ||||||
| Amgen Inc. | 27.56 | 25.22 | 22.82 | 25.81 | 24.59 | 23.15 | 25.49 | 38.24 | 40.68 | 53.65 | 44.38 | 23.14 | 18.09 | 16.31 | 16.18 | 19.56 | 21.00 | 20.03 | 22.23 | ||||||
| Bristol-Myers Squibb Co. | 13.58 | 14.27 | 17.01 | 17.30 | 15.38 | 17.46 | 18.29 | — | — | — | — | 12.27 | 13.01 | 15.93 | 19.43 | 23.97 | 23.71 | 24.14 | 25.64 | ||||||
| Danaher Corp. | 37.99 | 31.43 | 37.32 | 40.93 | 44.52 | 39.84 | 36.51 | 38.12 | 48.49 | 45.39 | 42.59 | 39.09 | 24.76 | 29.99 | 25.00 | 25.65 | 26.65 | 32.73 | 32.15 | ||||||
| Gilead Sciences Inc. | — | — | 18.06 | 21.54 | 18.18 | 21.68 | 20.62 | 296.57 | 925.87 | 89.29 | 166.76 | 16.17 | 17.10 | 17.88 | 17.75 | 22.68 | 29.30 | 18.66 | 17.25 | ||||||
| Johnson & Johnson | 38.56 | 29.70 | 25.87 | 21.66 | 18.51 | 18.02 | 17.14 | 26.92 | 27.19 | 10.11 | 9.46 | 10.73 | 10.12 | 33.35 | 33.43 | 22.97 | 23.52 | 24.98 | 23.95 | ||||||
| Merck & Co. Inc. | 151.11 | 99.98 | 31.27 | 16.79 | 11.00 | 12.30 | 11.98 | 13.49 | 20.98 | 20.73 | 140.05 | 893.99 | 56.85 | 86.53 | 22.92 | 19.21 | 16.41 | 13.36 | 15.70 | ||||||
| Pfizer Inc. | 42.39 | 33.42 | 20.12 | 19.83 | 14.06 | 13.09 | 17.22 | 18.42 | 37.00 | — | — | 73.42 | 16.60 | 9.42 | 7.44 | 7.58 | 8.81 | 9.56 | 11.11 | ||||||
| Regeneron Pharmaceuticals Inc. | 19.93 | 17.56 | 16.27 | 18.19 | 15.03 | 13.29 | 13.65 | 17.76 | 19.79 | 27.88 | 26.78 | 25.99 | 22.35 | 19.48 | 19.77 | 19.68 | 14.98 | 11.67 | 9.15 | ||||||
| Thermo Fisher Scientific Inc. | 36.52 | 30.48 | 25.46 | 28.82 | 32.45 | 26.56 | 24.55 | 32.03 | 34.78 | 37.81 | 36.21 | 35.65 | 29.57 | 37.01 | 34.99 | 30.55 | 27.64 | 31.09 | 28.15 | ||||||
| Vertex Pharmaceuticals Inc. | 33.85 | 27.54 | 24.83 | 31.58 | 29.11 | 26.43 | — | — | — | — | 26.34 | 30.42 | 28.09 | 27.49 | 27.34 | 23.02 | 24.62 | 23.12 | 26.50 | ||||||
Based on: 10-Q (reporting date: 2026-09-30), 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Data adjusted for splits and stock dividends.
2 Q3 2026 Calculation
EPS
= (Net income (loss)Q3 2026
+ Net income (loss)Q2 2026
+ Net income (loss)Q1 2026
+ Net income (loss)Q4 2025)
÷ No. shares of common stock outstanding
= (6,451,000,000 + 7,095,000,000 + 7,396,000,000 + 6,637,700,000)
÷ 940,745,031 = 29.32
3 Closing price as at the filing date of Eli Lilly & Co. Quarterly or Annual Report.
4 Q3 2026 Calculation
P/E ratio = Share price ÷ EPS
= 1,373.70 ÷ 29.32 = 46.86
5 Click competitor name to see calculations.
The financial data exhibits a period of significant valuation expansion followed by a phase of earnings-driven normalization. Over the analyzed period from March 2022 to September 2026, the relationship between share price and earnings per share (EPS) shifted from speculative growth to a valuation supported by fundamental earnings growth.
- Share Price Trajectory
- A strong upward trend in share price is observed, increasing from 292.13 USD in March 2022 to a peak of 1,373.70 USD by September 2026. While the growth was generally consistent, a notable period of volatility occurred between March 2025 and June 2025, where the price experienced a temporary decline before resuming its ascent.
- Earnings Per Share (EPS) Growth
- EPS remained relatively stagnant between March 2022 and December 2023, fluctuating within a narrow range of 5.25 USD to 6.84 USD. However, beginning in March 2024, a period of accelerated growth is evident. EPS rose from 6.46 USD in March 2024 to 29.32 USD by September 2026, representing a substantial increase in bottom-line profitability over the latter half of the period.
- Price-to-Earnings (P/E) Ratio Dynamics
- The P/E ratio underwent three distinct phases. First, a phase of rapid expansion occurred between March 2022 and December 2023, where the ratio climbed from 45.29 to a peak of 135.24, indicating that share price appreciation significantly outpaced earnings growth. Second, a correction phase occurred between March 2024 and June 2025, during which the P/E ratio declined from 120.94 to 43.95. This compression was driven by the rapid acceleration of EPS, which effectively "caught up" to the inflated share price. Finally, a stabilization phase is observed from September 2025 through September 2026, with the P/E ratio oscillating between 34.82 and 46.86.
In summary, the valuation transitioned from an aggressive multiple peak in late 2023 to a more sustainable level by 2026. The convergence of a rising share price with an exponentially growing EPS resulted in a normalization of the P/E ratio, suggesting that the market's premium for the stock became increasingly justified by actual financial performance.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Price to Operating Profit (P/OP)
| Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | 940,745,031 | 941,357,065 | 941,741,406 | 943,357,420 | 945,383,757 | 946,456,759 | 947,735,651 | 948,169,999 | 949,315,694 | 950,425,778 | 950,405,386 | 950,164,452 | 949,307,237 | 949,295,173 | 949,272,933 | 950,296,118 | 950,177,900 | 950,174,817 | 950,159,559 | ||||||
| Selected Financial Data (US$) | |||||||||||||||||||||||||
| Operating income (in millions) | 8,608) | 8,978) | 8,915) | 8,374) | 7,366) | 6,867) | 3,695) | 5,149) | 1,526) | 3,715) | 2,509) | 2,388) | 450) | 2,126) | 1,494) | 1,836) | 1,677) | 1,210) | 2,404) | ||||||
| Operating profit per share2 | 37.07 | 35.73 | 33.47 | 27.88 | 24.41 | 18.21 | 14.86 | 13.60 | 10.68 | 9.53 | 7.86 | 6.80 | 6.22 | 7.51 | 6.55 | 7.50 | 7.59 | 7.80 | 8.01 | ||||||
| Share price1, 3 | 1,373.70 | 1,169.86 | 934.60 | 1,038.27 | 844.50 | 640.86 | 794.10 | 867.05 | 846.83 | 845.31 | 781.10 | 745.91 | 580.29 | 521.60 | 390.35 | 329.07 | 352.58 | 305.79 | 292.13 | ||||||
| Valuation Ratio | |||||||||||||||||||||||||
| P/OP ratio4 | 37.05 | 32.74 | 27.92 | 37.24 | 34.60 | 35.19 | 53.43 | 63.73 | 79.30 | 88.66 | 99.34 | 109.75 | 93.27 | 69.42 | 59.60 | 43.88 | 46.48 | 39.20 | 36.49 | ||||||
| Benchmarks | |||||||||||||||||||||||||
| P/OP Ratio, Competitors5 | |||||||||||||||||||||||||
| AbbVie Inc. | 23.81 | 25.67 | 23.23 | 26.37 | 42.20 | 31.76 | 32.37 | 37.26 | 25.63 | 26.99 | 22.62 | 24.34 | 16.55 | 15.26 | 16.15 | 14.78 | 14.52 | 14.12 | 14.57 | ||||||
| Amgen Inc. | 20.52 | 19.30 | 16.84 | 21.92 | 19.86 | 18.71 | 20.31 | 21.55 | 27.68 | 27.12 | 23.97 | 19.69 | 15.45 | 13.71 | 14.25 | 13.40 | 14.89 | 14.08 | 15.88 | ||||||
| Bristol-Myers Squibb Co. | 10.86 | 11.30 | 12.42 | 12.20 | 10.25 | 11.07 | 13.65 | — | — | — | — | 13.53 | 14.14 | 16.24 | 17.09 | 18.29 | 17.79 | 18.62 | 20.32 | ||||||
| Danaher Corp. | 31.53 | 24.54 | 28.93 | 31.54 | 33.80 | 30.79 | 28.49 | 30.56 | 39.52 | 38.14 | 37.52 | 35.64 | 23.61 | 27.01 | 21.31 | 20.97 | 20.71 | 25.91 | 26.48 | ||||||
| Gilead Sciences Inc. | — | — | 16.05 | 18.29 | 14.06 | 17.00 | 14.96 | 85.65 | 143.05 | 36.80 | 51.26 | 12.05 | 12.16 | 11.57 | 11.21 | 14.21 | 16.27 | 11.02 | 10.78 | ||||||
| Johnson & Johnson | 25.09 | 24.10 | 21.40 | 22.95 | 19.83 | 19.04 | 17.74 | 18.20 | 18.65 | 17.54 | 16.96 | 17.78 | 15.69 | 18.91 | 18.26 | 17.62 | 19.64 | 20.45 | 21.06 | ||||||
| Merck & Co. Inc. | 67.93 | 49.74 | 23.37 | 14.44 | 9.67 | 10.57 | 10.37 | 11.60 | 18.67 | 18.41 | 75.94 | 138.56 | 33.75 | 44.67 | 18.53 | 15.55 | 13.85 | 11.72 | 14.29 | ||||||
| Pfizer Inc. | 12.54 | 10.48 | 10.37 | 10.82 | 10.07 | 9.49 | 11.27 | 11.92 | 27.24 | — | — | 121.63 | 17.49 | 9.17 | 6.74 | 6.80 | 7.82 | 9.11 | 11.49 | ||||||
| Regeneron Pharmaceuticals Inc. | 19.73 | 19.78 | 19.83 | 22.90 | 18.65 | 15.42 | 16.03 | 19.63 | 23.18 | 30.86 | 26.82 | 25.39 | 21.13 | 19.32 | 18.68 | 18.01 | 12.91 | 9.68 | 7.98 | ||||||
| Thermo Fisher Scientific Inc. | 30.50 | 26.07 | 22.09 | 24.94 | 28.40 | 23.62 | 21.64 | 27.65 | 29.74 | 32.66 | 31.40 | 31.16 | 25.59 | 31.55 | 29.54 | 25.30 | 21.43 | 23.99 | 21.84 | ||||||
| Vertex Pharmaceuticals Inc. | 31.27 | 25.40 | 23.01 | 29.92 | 26.79 | 24.50 | — | — | — | — | 25.25 | 28.74 | 25.14 | 23.33 | 22.03 | 17.75 | 19.41 | 18.11 | 22.13 | ||||||
Based on: 10-Q (reporting date: 2026-09-30), 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Data adjusted for splits and stock dividends.
2 Q3 2026 Calculation
Operating profit per share
= (Operating incomeQ3 2026
+ Operating incomeQ2 2026
+ Operating incomeQ1 2026
+ Operating incomeQ4 2025)
÷ No. shares of common stock outstanding
= (8,608,000,000 + 8,978,000,000 + 8,915,000,000 + 8,374,400,000)
÷ 940,745,031 = 37.07
3 Closing price as at the filing date of Eli Lilly & Co. Quarterly or Annual Report.
4 Q3 2026 Calculation
P/OP ratio = Share price ÷ Operating profit per share
= 1,373.70 ÷ 37.07 = 37.05
5 Click competitor name to see calculations.
The Price to Operating Profit (P/OP) ratio exhibits a cyclical trajectory characterized by an aggressive valuation expansion followed by a period of fundamental alignment. Between March 2022 and December 2023, the ratio shifted from 36.49 to a peak of 109.75, indicating that market pricing significantly outpaced operational earnings growth during this window.
- Valuation Expansion Phase (2022–2023)
- During this period, a strong positive correlation is observed between the share price and the P/OP ratio. While the share price climbed from 292.13 to 745.91, the operating profit per share remained relatively stagnant, fluctuating between 6.22 and 8.01. This divergence resulted in a rapid inflation of the valuation multiple, peaking in December 2023.
- Fundamental Convergence Phase (2024–2025)
- A reversal in the P/OP trend occurred starting in March 2024, as operating profit per share began a period of accelerated growth. Despite the share price continuing to reach new highs, the operating profit per share increased from 7.86 in March 2024 to 18.21 by June 2025. This surge in operational performance acted as a corrective force, compressing the P/OP ratio from its peak down to 34.60 by June 2025.
- Stabilization and Scaling Phase (2025–2026)
- In the final periods analyzed, the P/OP ratio entered a stage of relative stability, fluctuating within a narrow range between 27.92 and 37.05. This stabilization coincides with a synchronized increase in both share price and profitability. By September 2026, the share price reached 1,373.70 and the operating profit per share reached 37.07, suggesting that the valuation has returned to levels consistent with the initial 2022 baseline, despite the absolute values of both metrics being substantially higher.
Overall, the data reflects a transition from a speculative valuation driven by price appreciation to a fundamentally supported valuation driven by substantial growth in operating profitability.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Price to Sales (P/S)
| Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | 940,745,031 | 941,357,065 | 941,741,406 | 943,357,420 | 945,383,757 | 946,456,759 | 947,735,651 | 948,169,999 | 949,315,694 | 950,425,778 | 950,405,386 | 950,164,452 | 949,307,237 | 949,295,173 | 949,272,933 | 950,296,118 | 950,177,900 | 950,174,817 | 950,159,559 | ||||||
| Selected Financial Data (US$) | |||||||||||||||||||||||||
| Revenue (in millions) | 24,397) | 22,974) | 19,799) | 19,292) | 17,601) | 15,558) | 12,729) | 13,533) | 11,439) | 11,303) | 8,768) | 9,353) | 9,499) | 8,312) | 6,960) | 7,302) | 6,942) | 6,488) | 7,810) | ||||||
| Sales per share2 | 91.91 | 84.63 | 76.72 | 69.09 | 62.85 | 56.27 | 51.71 | 47.50 | 43.05 | 40.95 | 37.81 | 35.91 | 33.79 | 31.09 | 29.17 | 30.03 | 30.77 | 30.60 | 30.86 | ||||||
| Share price1, 3 | 1,373.70 | 1,169.86 | 934.60 | 1,038.27 | 844.50 | 640.86 | 794.10 | 867.05 | 846.83 | 845.31 | 781.10 | 745.91 | 580.29 | 521.60 | 390.35 | 329.07 | 352.58 | 305.79 | 292.13 | ||||||
| Valuation Ratio | |||||||||||||||||||||||||
| P/S ratio4 | 14.95 | 13.82 | 12.18 | 15.03 | 13.44 | 11.39 | 15.36 | 18.25 | 19.67 | 20.64 | 20.66 | 20.77 | 17.18 | 16.78 | 13.38 | 10.96 | 11.46 | 9.99 | 9.47 | ||||||
| Benchmarks | |||||||||||||||||||||||||
| P/S Ratio, Competitors5 | |||||||||||||||||||||||||
| AbbVie Inc. | 7.66 | 6.73 | 5.67 | 6.50 | 6.40 | 5.97 | 5.68 | 6.04 | 6.38 | 6.02 | 5.32 | 5.72 | 4.52 | 4.74 | 4.60 | 4.61 | 4.44 | 4.28 | 4.76 | ||||||
| Amgen Inc. | 6.99 | 6.08 | 5.02 | 5.66 | 4.99 | 4.57 | 4.61 | 4.88 | 5.53 | 5.68 | 5.93 | 5.78 | 5.34 | 5.14 | 5.14 | 5.17 | 5.85 | 5.35 | 5.21 | ||||||
| Bristol-Myers Squibb Co. | 2.51 | 2.69 | 2.55 | 2.53 | 1.93 | 1.85 | 2.08 | 2.36 | 2.38 | 2.20 | 1.99 | 2.19 | 2.40 | 2.81 | 3.10 | 3.29 | 3.39 | 3.39 | 3.41 | ||||||
| Danaher Corp. | 6.42 | 5.01 | 5.56 | 6.02 | 6.43 | 5.66 | 5.77 | 6.23 | 7.95 | 8.10 | 7.90 | 7.76 | 5.63 | 6.77 | 5.76 | 5.79 | 5.66 | 6.59 | 6.68 | ||||||
| Gilead Sciences Inc. | 6.88 | 5.44 | 5.69 | 6.34 | 5.16 | 4.76 | 4.31 | 4.98 | 4.18 | 3.41 | 2.97 | 3.40 | 3.69 | 3.61 | 3.70 | 3.86 | 3.64 | 2.84 | 2.86 | ||||||
| Johnson & Johnson | 6.25 | 6.38 | 5.65 | 6.16 | 5.04 | 4.51 | 4.19 | 4.26 | 4.55 | 4.44 | 4.25 | 4.43 | 4.01 | 4.84 | 4.60 | 4.34 | 4.69 | 4.80 | 5.00 | ||||||
| Merck & Co. Inc. | 5.50 | 4.77 | 4.25 | 4.71 | 3.26 | 3.17 | 3.27 | 3.60 | 4.03 | 4.56 | 5.26 | 5.43 | 4.42 | 4.62 | 5.16 | 4.71 | 4.25 | 3.87 | 4.12 | ||||||
| Pfizer Inc. | 2.69 | 2.27 | 2.38 | 2.46 | 2.20 | 2.20 | 2.17 | 2.32 | 2.60 | 3.00 | 2.86 | 2.61 | 2.51 | 2.58 | 2.32 | 2.37 | 2.63 | 2.77 | 3.00 | ||||||
| Regeneron Pharmaceuticals Inc. | 5.68 | 4.89 | 4.82 | 5.71 | 4.83 | 4.17 | 4.36 | 5.52 | 6.65 | 8.93 | 7.89 | 7.84 | 6.81 | 6.61 | 6.69 | 7.01 | 5.87 | 4.66 | 4.40 | ||||||
| Thermo Fisher Scientific Inc. | 5.45 | 4.58 | 3.86 | 4.34 | 4.87 | 4.05 | 3.73 | 4.73 | 5.04 | 5.55 | 5.14 | 4.99 | 4.05 | 4.87 | 4.81 | 4.73 | 4.40 | 5.40 | 5.20 | ||||||
| Vertex Pharmaceuticals Inc. | 10.39 | 9.64 | 8.82 | 10.40 | 9.13 | 8.42 | 10.41 | 10.78 | 12.12 | 12.35 | 10.39 | 11.16 | 10.10 | 9.73 | 9.68 | 8.56 | 9.26 | 8.85 | 8.17 | ||||||
Based on: 10-Q (reporting date: 2026-09-30), 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Data adjusted for splits and stock dividends.
2 Q3 2026 Calculation
Sales per share
= (RevenueQ3 2026
+ RevenueQ2 2026
+ RevenueQ1 2026
+ RevenueQ4 2025)
÷ No. shares of common stock outstanding
= (24,397,000,000 + 22,974,000,000 + 19,799,000,000 + 19,292,000,000)
÷ 940,745,031 = 91.91
3 Closing price as at the filing date of Eli Lilly & Co. Quarterly or Annual Report.
4 Q3 2026 Calculation
P/S ratio = Share price ÷ Sales per share
= 1,373.70 ÷ 91.91 = 14.95
5 Click competitor name to see calculations.
The financial trajectory from March 2022 through September 2026 is characterized by a substantial increase in both share price and sales per share, resulting in a volatile Price to Sales (P/S) ratio that reflects shifting market valuation premiums.
- Revenue and Price Growth
- Sales per share exhibited a consistent upward trend throughout the analyzed period, rising from 30.86 US$ in March 2022 to 91.91 US$ by September 2026. Simultaneously, the share price experienced significant appreciation, growing from 292.13 US$ to 1,373.70 US$. While both metrics increased, the rate of growth for the share price frequently outpaced revenue growth, driving the fluctuations in the P/S ratio.
- P/S Ratio Expansion Phase
- A period of aggressive valuation expansion occurred between March 2022 and December 2023. The P/S ratio rose from 9.47 to a peak of 20.77. This expansion indicates that the market was pricing in future growth expectations far in advance of the realized sales per share increases during this interval.
- Valuation Compression and Correction
- Following the peak in December 2023, a contraction in the P/S ratio is observed, reaching a low of 11.39 by June 2025. This decline occurred despite the continued growth in sales per share, suggesting a market correction or a period where revenue growth began to catch up with previous price premiums.
- Stabilization and Recent Trends
- From July 2025 to September 2026, the P/S ratio entered a phase of moderate volatility, fluctuating between 12.18 and 15.03. The final reading of 14.95 indicates a valuation that remains higher than the 2022 baseline but is significantly more tempered than the levels seen at the end of 2023.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Price to Book Value (P/BV)
| Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | 940,745,031 | 941,357,065 | 941,741,406 | 943,357,420 | 945,383,757 | 946,456,759 | 947,735,651 | 948,169,999 | 949,315,694 | 950,425,778 | 950,405,386 | 950,164,452 | 949,307,237 | 949,295,173 | 949,272,933 | 950,296,118 | 950,177,900 | 950,174,817 | 950,159,559 | ||||||
| Selected Financial Data (US$) | |||||||||||||||||||||||||
| Total Eli Lilly and Company shareholders’ equity (in millions) | 40,271) | 33,879) | 31,198) | 26,535) | 23,793) | 18,273) | 15,765) | 14,192) | 14,240) | 13,562) | 12,812) | 10,772) | 11,220) | 11,064) | 11,190) | 10,650) | 10,070) | 8,545) | 9,331) | ||||||
| Book value per share (BVPS)2 | 42.81 | 35.99 | 33.13 | 28.13 | 25.17 | 19.31 | 16.63 | 14.97 | 15.00 | 14.27 | 13.48 | 11.34 | 11.82 | 11.65 | 11.79 | 11.21 | 10.60 | 8.99 | 9.82 | ||||||
| Share price1, 3 | 1,373.70 | 1,169.86 | 934.60 | 1,038.27 | 844.50 | 640.86 | 794.10 | 867.05 | 846.83 | 845.31 | 781.10 | 745.91 | 580.29 | 521.60 | 390.35 | 329.07 | 352.58 | 305.79 | 292.13 | ||||||
| Valuation Ratio | |||||||||||||||||||||||||
| P/BV ratio4 | 32.09 | 32.51 | 28.21 | 36.91 | 33.55 | 33.19 | 47.74 | 57.93 | 56.45 | 59.24 | 57.94 | 65.80 | 49.10 | 44.75 | 33.11 | 29.36 | 33.27 | 34.00 | 29.75 | ||||||
| Benchmarks | |||||||||||||||||||||||||
| P/BV Ratio, Competitors5 | |||||||||||||||||||||||||
| AbbVie Inc. | — | — | — | — | — | — | 229.63 | 102.40 | 58.73 | 48.87 | 36.12 | 29.97 | 20.61 | 20.62 | 19.68 | 15.52 | 16.06 | 16.76 | 16.59 | ||||||
| Amgen Inc. | 18.03 | 18.86 | 19.37 | 22.99 | 17.91 | 20.63 | 24.36 | 26.61 | 22.86 | 28.34 | 33.25 | 24.94 | 17.87 | 19.19 | 23.95 | 35.01 | 39.30 | 54.46 | 138.87 | ||||||
| Bristol-Myers Squibb Co. | 5.36 | 5.94 | 6.17 | 6.61 | 5.01 | 5.06 | 5.70 | 6.98 | 6.60 | 6.01 | 5.49 | 3.35 | 3.72 | 3.97 | 4.46 | 4.88 | 4.85 | 4.90 | 5.07 | ||||||
| Danaher Corp. | 3.07 | 2.39 | 2.60 | 2.82 | 3.05 | 2.60 | 2.70 | 3.00 | 3.68 | 3.82 | 3.51 | 3.47 | 2.78 | 3.65 | 3.33 | 3.64 | 3.77 | 4.36 | 4.36 | ||||||
| Gilead Sciences Inc. | 16.23 | 13.72 | 7.08 | 8.07 | 6.85 | 6.96 | 6.42 | 7.36 | 6.36 | 5.15 | 4.61 | 4.01 | 4.50 | 4.63 | 4.72 | 4.90 | 4.63 | 3.82 | 3.91 | ||||||
| Johnson & Johnson | 7.61 | 7.35 | 6.70 | 7.12 | 5.86 | 5.20 | 4.79 | 5.30 | 5.69 | 5.37 | 5.20 | 5.48 | 4.92 | 5.79 | 6.00 | 5.37 | 6.04 | 6.01 | 6.36 | ||||||
| Merck & Co. Inc. | 8.26 | 7.57 | 6.09 | 5.82 | 4.04 | 4.12 | 4.32 | 4.99 | 5.73 | 6.53 | 8.00 | 8.68 | 6.35 | 6.96 | 6.38 | 6.07 | 5.63 | 5.12 | 5.44 | ||||||
| Pfizer Inc. | 1.92 | 1.70 | 1.67 | 1.78 | 1.49 | 1.59 | 1.50 | 1.68 | 1.70 | 1.92 | 1.74 | 1.75 | 1.80 | 2.04 | 2.14 | 2.48 | 2.83 | 3.21 | 3.37 | ||||||
| Regeneron Pharmaceuticals Inc. | 2.87 | 2.40 | 2.29 | 2.62 | 2.22 | 1.98 | 2.09 | 2.67 | 3.14 | 4.27 | 3.83 | 3.96 | 3.58 | 3.49 | 3.52 | 3.77 | 3.75 | 3.21 | 3.65 | ||||||
| Thermo Fisher Scientific Inc. | 4.72 | 4.03 | 3.36 | 3.62 | 4.18 | 3.46 | 3.24 | 4.09 | 4.36 | 4.96 | 4.80 | 4.57 | 3.88 | 4.84 | 4.99 | 4.83 | 4.46 | 5.47 | 5.23 | ||||||
| Vertex Pharmaceuticals Inc. | 6.44 | 5.99 | 5.56 | 6.69 | 6.18 | 5.60 | 7.01 | 7.24 | 8.24 | 8.64 | 5.71 | 6.26 | 5.90 | 5.98 | 6.18 | 5.50 | 6.18 | 6.19 | 5.95 | ||||||
Based on: 10-Q (reporting date: 2026-09-30), 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Data adjusted for splits and stock dividends.
2 Q3 2026 Calculation
BVPS = Total Eli Lilly and Company shareholders’ equity ÷ No. shares of common stock outstanding
= 40,271,000,000 ÷ 940,745,031 = 42.81
3 Closing price as at the filing date of Eli Lilly & Co. Quarterly or Annual Report.
4 Q3 2026 Calculation
P/BV ratio = Share price ÷ BVPS
= 1,373.70 ÷ 42.81 = 32.09
5 Click competitor name to see calculations.
The financial data reveals a significant evolution in the valuation of common stock from March 2022 through September 2026, characterized by a period of extreme multiple expansion followed by a transition toward stabilization.
- Price to Book Value (P/BV) Trend
- The P/BV ratio exhibited three distinct phases. From March 2022 to December 2022, the ratio remained relatively stable, fluctuating between 29.36 and 34.00. A period of rapid escalation occurred throughout 2023, with the ratio peaking at 65.80 in December 2023. This indicates a significant increase in market optimism or perceived future growth relative to the company's net asset value. From March 2024 through September 2026, the ratio experienced a gradual decompression, eventually settling into a range between 28.21 and 36.91.
- Book Value per Share (BVPS) Growth
- A consistent upward trajectory in the book value per share is observed over the entire period. BVPS grew from 9.82 in March 2022 to 42.81 by September 2026. The growth accelerated notably starting in 2024, providing a stronger fundamental basis for the stock's valuation and contributing to the moderation of the P/BV ratio during the latter half of the analyzed period.
- Share Price Dynamics
- The share price demonstrated an overall strong bullish trend, increasing from 292.13 in March 2022 to 1,373.70 in September 2026. While the price growth was substantial, the volatility of the P/BV ratio suggests that market pricing grew at a disproportionately faster rate than the underlying book value between early 2023 and late 2024, before the growth in BVPS began to align more closely with the share price appreciation in 2025 and 2026.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?